Abstract

Acadia Healthcare will release its Q2 2026 results on July 28, 2026 Post-Mkt; this preview compiles last quarter’s performance, current-quarter forecasts for revenue, margin and EPS, and a synthesis of institutional views from January 1, 2026 to July 21, 2026.

Market Forecast

Consensus for the current quarter points to revenue of 0.84 billion US dollars, EBIT of 0.09 billion US dollars, and EPS of 0.35, with year-over-year changes of 0.50%, -32.07%, and -50.07%, respectively; year-over-year notches reflect ratio-to-percent conversion. Company-level margin guidance implied by recent trend data suggests gross margin near the low-40% area and a softer net margin given elevated operating costs; if gross margin holds around the prior quarter’s 40.09% and operating leverage remains moderate, the net margin may track below recent average while adjusted EPS compresses year over year. Main business momentum remains tied to patient days and payer mix improvement in Medicaid and commercial contracts; the near-term outlook highlights steady bed additions and stable occupancy supporting revenue stability. The highest potential growth area remains Medicaid-funded services, which generated 0.50 billion US dollars last quarter and is positioned for mid-single-digit growth as new programs and state rates phase in.

Last Quarter Review

In the previous quarter, Acadia Healthcare reported revenue of 0.83 billion US dollars, a gross margin of 40.09%, GAAP net profit attributable to shareholders of 4.11 million US dollars with a net profit margin of 0.50%, and adjusted EPS of 0.37, with revenue rising 7.57% year over year and adjusted EPS declining 7.50% year over year. Capital deployment centered on capacity expansion and service mix optimization, while EBIT came in below expectations as cost inflation and development expenses weighed on operating leverage. Main business highlights: Medicaid revenue was 0.50 billion US dollars, commercial revenue was 0.19 billion US dollars, Medicare revenue was 0.12 billion US dollars, self-pay revenue was 0.01 billion US dollars, and other revenue was 0.01 billion US dollars, with Medicaid remaining the largest contributor by mix.

Current Quarter Outlook

Main inpatient and acute behavioral services

Operational trends suggest patient-day growth remains the fulcrum for top-line performance. Management’s development pipeline and incremental bed openings typically translate into step-ups in available capacity, supporting low- to mid-single-digit revenue growth even under modest payer-rate backdrops. Given the forecast revenue of 0.84 billion US dollars and a year-over-year growth rate of 0.50%, expectations embed resilient demand but limited pricing acceleration; cost discipline around labor utilization and outsourced clinical support will be central to protecting margins if wage inflation persists. Utilization levels and case mix across Medicaid and commercial payers will likely determine whether gross margin can stay near the prior quarter’s 40.09%.

Medicaid-funded programs as the leading growth engine

Medicaid remained the largest revenue stream at 0.50 billion US dollars last quarter and is poised to drive incremental growth as state-level behavioral health funding continues to expand. Bed conversions and program certifications tied to Medicaid populations can lift occupancy and throughput, but reimbursements may cap margin expansion versus commercial payers. The forecast modest revenue growth alongside a projected EBIT decline of 32.00% year over year implies wage and start-up costs tied to new programs could dilute near-term profitability; successful onboarding of clinical staff and smoothing of referral networks are the swing factors. If Medicaid patient-day growth outpaces staffing capacity, temporary agency reliance could pressure unit economics until hiring pipelines normalize.

Key stock-price drivers this quarter

Margin trajectory is the most immediate determinant of share performance, given consensus for a sharp EBIT compression despite essentially flat revenue growth. Investors will focus on labor cost inflation, contract labor normalization, and the cadence of opening new facilities, as these dictate conversion from gross margin to operating income. Payer mix shifts will also matter: a higher share of Medicaid volumes supports scale and demand visibility but can compress blended yields; conversely, a richer commercial mix would favor EPS but could be partly offset by higher patient-acuity costs. Watch for commentary on development capital expenditures and timing of bed additions; cadence slippage could push revenue downstream while costs remain front-loaded, amplifying operating deleverage.

Analyst Opinions

Across institutional previews captured between January 1, 2026 and July 21, 2026, the majority stance is cautiously positive, emphasizing stable demand, solid bed expansion visibility, and manageable payer dynamics, while acknowledging margin pressure in the near term; the bullish-to-bearish ratio trends favorable for a constructive setup. Noted institutional commentary highlights expectations that revenue growth should remain intact around the low single digits this quarter, with full-year growth anchored by new beds and program ramps. Analysts point to improving referral pipelines and steady state funding as supportive of the revenue base, with the main debate centered on labor cost normalization and the pace at which new capacity turns profitable. The consensus majority expects EPS pressure in the quarter but anticipates sequential improvement as development drags fade and labor markets loosen, framing any margin stabilization signals as a positive stock catalyst.